Examinando por Autor "Figueroa-Protti, Lucia"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 1 de 1
  • Miniatura
    Ítem
    Difference in mortality rates in hospitalized COVID-19 patients identified by cytokine profile clustering using a machine learning approach: An outcome prediction alternative
    (Los autores, 2022-09-20) Castro-Castro, Ana Cristina; Figueroa-Protti, Lucia; Molina-Mora, Jose Arturo; Rojas-Salas, María Paula; Villafuerte-Mena, Danae; Suarez-Sánchez, María José; Sanabría-Castro, Alfredo; Boza-Calvo, Carolina; Calvo-Flores, Leonardo; Solano-Vargas, Mariela; Madrigal-Sánchez, Juan José; Sibaja-Campos, Mario; Silesky-Jiménez, Juan Ignacio; Chaverri-Fernández, José Miguel; Soto-Rodríguez, Andrés; Echeverri-McCandless, Ann; Rojas-Chaves, Sebastián; Landaverde-Recinos, Denis; Weigert, Andreas; Mora, Javier
    COVID-19 is a disease caused by the novel Coronavirus SARS-CoV-2 causing an acute respiratory disease that can eventually lead to severe acute respiratory syndrome (SARS). An exacerbated inflammatory response is characteristic of SARS-CoV-2 infection, which leads to a cytokine release syndrome also known as cytokine storm associated with the severity of the disease. Considering the importance of this event in the immunopathology of COVID-19, this study analyses cytokine levels of hospitalized patients to identify cytokine profiles associated with severity and mortality. Using a machine learning approach, 3 clusters of COVID-19 hospitalized patients were created based on their cytokine profile. Significant differences in the mortality rate were found among the clusters, associated to different CXCL10/IL-38 ratio. The balance of a CXCL10 induced inflammation with an appropriate immune regulation mediated by the anti-inflammatory cytokine IL-38 appears to generate the adequate immune context to overrule SARS-CoV-2 infection without creating a harmful inflammatory reaction. This study supports the concept that analyzing a single cytokine is insufficient to determine the outcome of a complex disease such as COVID-19, and different strategies incorporating bioinformatic analyses considering a broader immune profile represent a more robust alternative to predict the outcome of hospitalized patients with SARS-CoV-2 infection